 Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
| Descriptor ID |
D040262
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950 D12.776.543.750.060.750 D12.776.543.750.750.400.910
|
| Concept/Terms |
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Permeability Factor
- Vascular Endothelial Cell Growth Factor Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- VEGF Receptors
- Receptors, VEGF
- VPF Receptor
- Receptor, Vascular Endothelial Cell Growth Factor
- Vascular Permeability Factor Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in this website by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 0 | 4 | 4 | | 2012 | 2 | 2 | 4 | | 2013 | 0 | 4 | 4 | | 2014 | 1 | 2 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
-
Mansour SG, Zhang WR, Moledina DG, Coca SG, Jia Y, Thiessen-Philbrook H, McArthur E, Inoue K, Koyner JL, Shlipak MG, Wilson FP, Garg AX, Ishibe S, Parikh CR. The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery. Am J Kidney Dis. 2019 07; 74(1):36-46.
-
Sahni S, Watson RM, Sheth VS. ACTINOMYCES NEUII ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION. Retin Cases Brief Rep. 2017 Summer; 11(3):281-282.
-
Nariani A, Williams B, Hariprasad SM. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian J Ophthalmol. 2016 Sep; 64(9):643-647.
-
Wykoff CC, Hariprasad SM. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 01; 47(4):308-12.
-
Moshfeghi DM, Hariprasad SM, Marx JL, Thompson D, Soo Y, Gibson A, Saroj N, Vitti R, Heier JS. Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar; 47(3):238-44.
-
Wykoff CC, Hariprasad SM. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
-
Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13.
-
Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89.
-
Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|